This activity was originally presented at the 2026 Breast
Cancer Day of Education.
In collaboration with HOPA & COA.
Program Description
The PI3K/AKT/mTOR pathway is a central driver of endocrine resistance in hormone receptor–positive (HR+) metastatic breast cancer (mBC). As endocrine resistance remains a significant clinical challenge driven in part by alterations in the PI3K/AKT/mTOR signaling pathway, targeted therapeutics have become a critical component of care. This session examines aberrant signaling through this pathway that enables ligand-independent estrogen receptor activation, necessitating the strategic use of targeted inhibitors to restore endocrine sensitivity. A major focus will be the application of PI3K/AKT inhibitors in frontline, high-risk endocrine-resistant mBC, post-CDK4/6 inhibitor treatment sequencing, and the mechanistic advantages of investigational pan-pathway and dual inhibitors. Through interactive audience response segments, speakers will guide participants through case-based clinical scenarios, highlighting key factors that inform real-world selection including eligibility criteria, high-risk status, biomarker and mutation testing, treatment access and prior authorizations, expected toxicities, and adherence concerns.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 30, 2026
Expiration date: July 30, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.25 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify patients who are appropriate candidates for PI3K or AKT inhibitor–based therapy in frontline and relapsed hormone receptor–positive/HER2-negative (HR+/HER2−) metastatic breast cancer, incorporating biomarker status and clinical features
- Analyze how key PI3K and AKT inhibitor trial data inform real-world treatment selection and sequencing decisions in HR+/HER2− metastatic breast cancer
- Determine proactive monitoring and management strategies for endocrine toxicities associated with PI3K and AKT inhibitors to support treatment adherence and continuity of care
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
